Other Indicators Sample Clauses

Other Indicators. The M&E Plan will contain the Indicators listed in the following tables. Objective Level Increased responsiveness of Local Government Units (LGUs) to community needs Use of inclusive Community Driven Development (CDD) processes by local governments Percentage of project municipal local government units (MLGUs) that have meetings with community representatives to solicit inputs to municipal development plans and / or percentage of barangays that reflect community priorities in their barangay development plans TBD 80% LGU provision of funds for O&M Percentage of MLGUs that provide funding support for KALAHI-CIDSS sub-project O&M 0% 80% LGU application of CDD practices to non-KALAHI- CIDSS activities Number of project MLGUs that pass ordinances / resolutions adopting CDD principles XXX XXX Increased community engagement in development activities Participation of women in local government Number of women representatives in targeted areas XXX XXX Community engagement in development activities Percentage of MCC-funded KALAHI-CIDSS-developed community organizations that have satisfactory organizational performance ratings 0% 80% Percentage of communities that attract additional funding for development activities after the KALAHI-CIDSS Project is completed 0% 30% Increased value of sub-project benefits6 Aggregate value of benefits of sub-projects. (Varies, please see below) Outcome Level Increased LGU engagement LGU provision of funds Percentage of LGUs that provide at least 80% of Memorandum of Agreement (MOA) funding requirements 0% 90% 4 As the municipalities are due to be randomly selected, baseline figures are not yet known. 5 These figures are indicative. 6 The baseline levels for these indicators will be determined by the initial round of data collection in the selected municipalities. The targets will be informed by this information and by the results of the endline data collection in KC1 areas. Table 1: M&E Indicators for KALAHI-CIDSS Project LGU provision of technical support Percentage of LGUs that provide at least 80% of MOA technical support requirements 0% 90% Increased community engagement Barangay assembly participation Percentage of barangay assemblies with 80% of community households represented TBD 80% Marginalized group participation Percentage of barangay assemblies with 65% of youth, women, indigenous people and poorest households represented TBD 80% Increased value of sub-project benefits7 Time savings XXX XXX Labor force participation (by a...
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Other Indicators. The M&E Plan will contain the Indicators listed in the following tables. Result Indicator Definition of Indicator Baseline3 Year 5 Incomes increase due to transition to high value agriculture interventions Increase in the annual profits of crop production per hectare Total annual profits of crop production in areas targeted by the Centralized Irrigation System Rehabilitation Activity (“Target Areas”) (excluding rent and labor cost) / total Target Areas (US$)4 180 390 Increase in the rent for land paid to lessors per hectare Average rent paid by lessee to lessor per hectare of rented land in Target Areas (US$)5 80 100 Increase in the wage bill paid to labor per hectare Value of labor (total person-days of labor × average daily wage excluding household labor) per annum / total Target Areas (US$)6 40 180 Increase in the annual profits among assisted farms outside of Target Areas Percent differential between the annual per hectare profit (excluding rent and labor costs) realized among assisted farms outside of Target Areas and a comparison farm group NA 20% Moldova has examples of a model for transition to high value agriculture in centrally irrigated areas and an enabling environment (legal, financial, and market) for replication of the model Increase in the area irrigated in Target Areas Number of hectares of irrigated crops (high value agriculture, grains and technical crops) in Target Areas7 1,100 3,460 Adoption of HVA crops in Target Areas Number of hectares of irrigated and non-irrigated high value agriculture crops (fruits, grapes, vegetables, potatoes, etc.) in Target Areas8 1,800 2,840 3 All currency figures are in 2009 values using a market conversion rate of 10.52 MDL/US$.
Sample 1Sample 2
Other Indicators. Documenting Disproportionate Impacts
Sample 1
Other Indicators. The M&E Plan will contain the Indicators listed in the following tables. Cross-Cutting Outcomes Improved household health Incidence of water-borne diseases Number of cases of infectious diarrhea and cholera per 1,000 population 138 per 1,000 32 per 1,000 Decreased economic impact of water-related diseases Days of work missed due to illness Average Number of days of work missed per beneficiary, per year (disaggregated by sex) TBD 18% reduction Days of school missed due to illness Average Number of days of school missed per school age beneficiary, per year (disaggregated by sex) TBD 20% reduction Improved water service coverage Access to improved water supply Number of new household connections to the water network made possible through the Compact 0 16,790 Volume of water produced Total volume of water produced in cubic meters per day for the service area 225,000 240,000 Reduced water losses Non-revenue water The difference between water supplied and water sold (i.e. volume of water “lost”) expressed as a percentage of water supplied. 48% 25% Time savings for households Time spent fetching water Average time spent by household members to fetch water in the past week (hours) (disaggregated by sex) 16 9.5 Improved water supply infrastructure Length of the water distribution network (km) Total length of the distribution network in km 1,372 1,547 Water points constructed The number of non-networked, stand- alone water supply systems constructed (kiosks) 532 596 Improved sanitation coverage Access to improved sanitation Number of new household connections to sewage network made possible through the Compact 0 13,147 Improved sanitation infrastructure Length of the sewer system Total length of the sewerage network in km 408 490
Sample 1
Other Indicators. The M&E Plan will contain the Indicators listed in the following tables. MCA-Malawi will update Baselines for key Indicators after new data becomes available, including the Malawi Integrated Household Survey III, after a new billing system is installed at ESCOM, and after a Cost of Service study and Integrated Resource Plan are completed. Indicators on outages and load shedding will be refined prior to entry into force of the Compact and during the first year of the Compact. Financial Targets and performance will be reviewed and updated regularly, as defined in Annex I of the Compact. 2 Poverty rates cited above are based on MCA-Malawi Core Team projections using poverty line of US$1.00 a day. Xxxxx X defines poverty line as US$1.25 a day. The following are Indicators and Targets for the monitoring of the Program Objective as further described in paragraph 2 of Part A of Xxxxx X. The Project is expected to contribute to the achievement of these Indicators and Targets, but is not solely responsible for the results.
Sample 1
Other Indicators. The M&E Plan will contain the Indicators listed in the following tables. MCA-Malawi will update Baselines for key Indicators after new data becomes available, including the Malawi Integrated Household Survey III, after a new billing system is installed at 1 Poverty rates cited above are based on MCA-Malawi Core Team projections using poverty line of US$1.00 a day. Annex I defines poverty line as US$1.25 a day. ESCOM, and after a Cost of Service analysis and Integrated Resource Plan are completed. Indicators on outages and load shedding will be refined prior to completion of the M&E Plan during the first year of the Compact. Financial Targets and performance will be reviewed and updated regularly, as defined in Annex I of the Compact.
Sample 1

Related to Other Indicators

  • Projects There shall be a thirty (30) km free zone around the projects excluding the Metro Vancouver Area. For local residents, kilometers shall be paid from the boundary of the free zone around the project. Workers employed by any contractor within an identified free zone who resides outside of that same free zone will be paid according to the Kilometer Chart from the project to their residence less thirty

  • Capabilities A. The Parties agree that the DRE must possess the legal, technical, and financial capacity to: (1) Accept and expend non-federal funds consistent with Section 4.2.4; (2) Accept transfer of the FERC license and title for the Facilities from PacifiCorp; (3) Seek and obtain necessary permits and other authorizations to implement Facilities Removal; (4) Enter into appropriate contracts and grant agreements for effectuating Facilities Removal; (5) Perform, directly or by oversight, Facilities Removal; (6) Prevent, mitigate, and respond to damages the DRE or any of its contractors, subcontractors, or assigns cause during the course of Facilities Removal, and, consistent with Applicable Law, respond to and defend associated liability claims against the DRE or any of its contractors, subcontractors, or assigns, including costs thereof and any judgments or awards resulting therefrom; (7) Carry the required insurance and bonding set forth in Appendix L to respond to liability and damages claims associated with Facilities Removal against the DRE or any of its contractors, subcontractors, or assigns; (8) Meet the deadlines set forth in Exhibit 4; and (9) Perform such other tasks as are reasonable and necessary for Facilities Removal. B. Before the DRE and PacifiCorp file the joint application to transfer the license for the Facilities, the DRE will Timely demonstrate to the reasonable satisfaction of the States and PacifiCorp that it possesses the legal, technical, and financial capacity to accomplish the tasks in Sections 7.1.2.A(1) through (5), (8), and (9). PacifiCorp and the States will consult if the DRE fails to make the demonstration required in this subsection. C. Within six months of the DRE’s execution of the Settlement, the DRE will include in an informational filing in the FERC license transfer proceeding proof that it possesses the legal, technical, and financial capacity to accomplish the tasks in Sections 7.1.2.A(6) and (7). This filing will include documentation that the DRE meets the requirements of Parts II, III, and IV of Appendix L and is capable of fulfilling its obligations under Section 7.1.3. The DRE will not provide the filing if either of the States or PacifiCorp objects to the filing after a reasonable opportunity to review before submission to FERC. The six-month deadline may be changed by agreement of the DRE, the States, and PacifiCorp. The Parties will Meet and Confer if the DRE fails to provide the informational filing to FERC.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Candidates The Superintendent or designee shall invite all current candidates for the office of Board member to attend:

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Internships The Hospital may establish internships for the purpose of meeting future projected nursing shortages and/or providing career opportunities where there are no internal qualified candidates for job postings. In such circumstances, the implementation and guidelines of such an arrangement will be determined locally by the Hospital and the Union subject to the following: Internships are designed to develop the Hospital’s staff in order to fill positions for which there are currently no qualified internal candidates and/or for which shortages are predicted within a five (5) year period. Internships enable hospitals to maximize the use of qualified internal staff to meet their human resources needs, while at the same time providing career development opportunities for their employees. To provide direction to the local parties in developing and implementing internship(s) the Ontario Nurses’ Association and Participating Hospitals have agreed to the following principles: (a) The Hospital will establish the expectations for each internship opportunity; (b) There will be an open application process for internship opportunities; (c) The opportunities will be open to currently employed nurses who can demonstrate continuous learning, and a commitment to the Hospital; (d) Nurses who are selected for internship opportunities will commit to continued employment on a mutually determined basis; (e) Initiatives to support selected candidates may include but are not limited to: i) No loss of regular wages while attending a requisite course ii) Paid course fees iii) Paid time for clinical practicums in the Hospital or another clinical site iv) Any other initiatives, as agreed. (f) Part-time nurses will be credited with seniority and service for all such hours paid while participating in these initiatives as provided above.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

  • MINISTRY INITIATIVES OSSTF/FEESO education workers will be an active participant in the consultation process at the Ministry Initiatives Committee. Ministry Initiatives Committee shall meet at least quarterly each year to discuss new initiatives, including implications for training, resources.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!